Solifenacin
ID: SPE2D2-25-R-0011Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/a957c72b9dd040e0a1f3105b8c155a4f/view
Timeline
    Description

    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the procurement of Solifenacin Succinate Tablets under Solicitation No. SPE2D2-25-R-0011. This procurement aims to secure various types and quantities of Solifenacin, a pharmaceutical product essential for treating overactive bladder symptoms. The solicitation outlines specific submission instructions via the Defense Logistics Agency Internet Bid Board System (DIBBS) and emphasizes compliance with federal acquisition regulations, including the requirement for a subcontracting plan from large businesses. Interested contractors should note that the closing date for offer submissions has been extended to June 5, 2025, at 3:00 PM EDT, and must acknowledge receipt of the amendment to ensure their offers remain valid. For further inquiries, potential bidders can contact Jayne Do at jayne.do@dla.mil or Jason C. Wray at Jason.Wray@dla.mil.

    Files
    Title
    Posted
    Amendment 0001.pdf
    This document is an amendment to a federal solicitation related to a contract identified by the code SPE2D225R0011. The primary purpose of the amendment is to extend the closing date for offer submissions from May 29, 2025, at 3:00 PM EDT to June 5, 2025, also at 3:00 PM EDT. It specifies that all other terms and conditions of the original solicitation remain unchanged. Contractors must acknowledge receipt of this amendment to ensure their offers remain valid, and they can do so by submitting a letter or telegram referencing the solicitation and amendment numbers. The document also includes administrative details regarding the contract modification process and contact information for the contracting officer, ensuring compliance with federal acquisition regulations. The amendment reiterates the importance of timely acknowledgment to avoid rejection of offers, facilitating a fair procurement process. Overall, this amendment reflects ongoing administrative adjustments typical in government contracting processes, highlighting the need for flexibility and clear communication with potential contractors.
    SPE2D2-25-R-0011 Solicitation - Solifenacin FINAL.pdf
    The document details Solicitation No. SPE2D2-25-R-0011, which outlines a federal Request for Proposals (RFP) for the procurement of Solifenacin Succinate Tablets, specifying various types, quantities, and delivery expectations. Key sections include submission instructions for offers through the Defense Logistics Agency Internet Bid Board System (DIBBS) and compliance requirements with federal acquisition regulations ensuring contractor integrity, performance evaluation, and ethics. The solicitation emphasizes the need for a subcontracting plan from large businesses and mandates reporting on subcontracting goals. It outlines contract clauses and terms that must be adhered to, including trade agreement stipulations and prohibitions against certain telecommunications equipment. The overall purpose of the document is to establish clear guidelines for potential contractors in submitting offers for pharmaceutical supplies while ensuring compliance with federal laws and regulations to promote fair contracting practices.
    Lifecycle
    Title
    Type
    Solifenacin
    Solicitation
    Solifenacin
    Currently viewing
    Presolicitation
    Similar Opportunities
    Metaxalone Tablets
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Metaxalone 800 MG tablets, available in 100-count and 500-count bottles. This procurement aims to establish a requirements contract with estimated annual quantities for a base year and four option years, emphasizing the need for compliance with various federal acquisition regulations and ethical standards. Metaxalone is a critical medication used for muscle relaxation, making this contract vital for supporting military health services. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between November 7 and December 7, 2025, by 3:00 PM EST. For further inquiries, contact Jeremy Brown at jeremy.brown@dla.mil or Jason Wray at Jason.wray@dla.mil.
    Sertraline Tablets
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting offers for the procurement of Sertraline Tablets in 25MG, 50MG, and 100MG dosages, with various bottle counts required over a base year and four option years. This solicitation, identified as SPE2D2-26-R-0002, is critical for ensuring the availability of this essential pharmaceutical, which is commonly used to treat depression and anxiety disorders among military personnel. Interested contractors must submit their offers electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by the extended deadline of December 17, 2025, at 3:00 PM EST, and are encouraged to contact Christopher Newman or Jason Wray for further inquiries regarding the solicitation.
    Ondansetron Orally Disintegrating Tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Rabeprazole Sodium Delayed Release Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    DLA MedSurg Prime Vendor Gen VI
    Dept Of Defense
    The Defense Logistics Agency (DLA) is seeking proposals for the Medical Surgical Prime Vendor (Med/Surg PV) Program, which aims to provide a comprehensive range of medical and surgical supplies across three Global Regions: North, South, and West. This procurement involves awarding Firm Fixed-Price Indefinite Delivery/Indefinite Quantity (IDIQ) contracts for both Primary and Backup Prime Vendors, facilitating routine ordering and contingency support for various military and federal healthcare facilities. The program is critical for ensuring the availability of essential medical supplies and equipment, supporting the operational readiness of Medical Treatment Facilities (MTFs) and clinics worldwide. Interested vendors must submit their proposals electronically via the DLA Internet Bid Board System (DIBBS) by January 8, 2026, at 3:00 PM Local Philadelphia Time, and can direct inquiries to Beatrice Lopez-Pollard at beatrice.lopez-pollard@dla.mil or Joshua Tankel at Joshua.Tankel@dla.mil.
    Metformin HCL
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Reactive and Inactive Skin Decontamination Lotion
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is seeking procurement for Reactive and Inactive Skin Decontamination Lotion (RSDL/ISDL). This contract involves the acquisition of specialized drugs and biologicals designed for decontaminating skin exposed to hazardous substances, which is critical for the safety and protection of military personnel in various operational environments. The opportunity is detailed in a redacted Justification and Approval document, indicating the importance of these products in maintaining troop readiness and safety. Interested vendors can reach out to Myrna I. Rodriguez at Myrna.Rodriguez@dla.mil or call 215.737.4711 for further information regarding this procurement.
    Ondansetron 4MG and 8MG
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ondansetron. This contract will establish a national supply source to provide Ondansetron HCL 4 and 8MG Tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The projected solicitation date is March of 2023.
    6505--Carbidopa Levodopa Immediate Release (IR) Tablets
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Carbidopa Levodopa Immediate Release (IR) Tablets, aimed at ensuring a reliable supply for various federal health care entities, including the VA, Department of Defense (DoD), and Bureau of Prisons (BOP). The procurement will involve awarding a single contract for an initial one-year period, with the possibility of four additional one-year option periods, to maintain an uninterrupted supply of these essential medications. The estimated annual requirements detail various dosages and package sizes, with total usage ranging from 2,008 to 118,764 bottles depending on the item. The solicitation is expected to be released around December 18, 2025, with a closing date of January 8, 2026; interested parties should direct inquiries to Ray Roldan at Raymond.Roldan@va.gov or call 708-786-4930.